Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
2(33%)
Results Posted
50%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
2
33%
Ph phase_2
1
17%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)

Detailed Status

Active, not recruiting2
Completed2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 21 (16.7%)
Phase 32 (33.3%)

Trials by Status

withdrawn117%
active_not_recruiting233%
completed233%
terminated117%

Recent Activity

2 active trials
Showing 5 of 6
active_not_recruitingphase_3

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

NCT03768063
active_not_recruitingphase_3

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789
terminatedphase_2

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02923739
completedphase_1

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

NCT02323191
completedphase_1

A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

NCT02760797
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03768063Phase 3

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active Not Recruiting
NCT05417789Phase 3

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Active Not Recruiting
NCT02923739Phase 2

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated
NCT02323191Phase 1

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

Completed
NCT02760797Phase 1

A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

Completed
NCT03369964Phase 1

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6